In the intricate and occasionally humorous world of medical discoveries, phosphodiesterase type 5 (PDE5) inhibitors stand out as a particularly fortunate accident. Originally developed in the late 1980s for treating angina—a common heart condition characterized by chest pain—these compounds initially failed to significantly improve cardiac symptoms.